Dr. Di Wu is the Director of Laboratory for International Research and Relations at Clinical Pharmacology & Therapeutics (CPT) in Children’s Hospital of Philadelphia (CHOP) and a Guest Professor at Central South University & Third Xiangya Hospital. Dr. Wu currently serves as Clinical Investigator, developing innovative designs for informative clinical trials and experiments and integrated approaches for data analysis at Kinetic Modeling and Simulation core of University of Pennsylvania/CHOP Clinical and Translation Science Award supported by NIH.

Adaptive design is especially useful in settings with low accrual rates such as pediatric or rare diseases trials. The mechanism combining phase I and phase II by integrating efficacy and toxicity to choose doses, could avoid time- and source-consuming conventional approachs of conducting a phase I trial based on safety alone followed by a phase II trial based on efficacy. In this interview Dr. Wu joins Andrea Charles from Pharma IQ, to discuss current trends in the pediatric research and development landscape, improved methods in paediatric clinical trials and utlising adaptive design methods.

[inlinead]